Important:
Information contained in the following UpToDate Talk podcasts was current at the time of initial release. However, this content is not maintained or updated. For current clinical recommendations, please always consult UpToDate Online. Please note that we are no longer producing new clinical podcasts.
UpToDate faculty discuss important changes to the practice of medicine based in our clinical podcasts. Our contributors are recognized physician leaders in their fields and offer their expertise regarding each update and its impact on clinical practice.
Support for UpToDate Talk is provided by UpToDate, Wolters Kluwer. UpToDate is entirely funded by the subscriptions of its users and does not accept advertising or funding unrelated to subscriptions. The opinions in such podcasts are entirely those of the discussants, and these discussants are authors and editors for UpToDate. View the UpToDate conflict of interest policy.
This is the complete archive for the UpToDate Clinical Talk Podcasts.
Edoxaban vs low molecular weight heparin in cancer-related VTE; New treatment for cystic fibrosis
Date Released: Feb 21 2018
Today’s UpToDate Talk episode features discussions related to three papers published in the New England Journal of Medicine. Dr. Jess Mandel discusses anticoagulation options for cancer-associated venous thromboembolism, and Dr. George Mallory discusses two studies of tezacaftor-ivacaftor in patients with cystic fibrosis. Segment two begins at 11:32. Dr. Helen Hollingsworth hosts.
Dr. Jess Mandel is Professor of Medicine and Vice Chair of the Division of Pulmonary, Critical Care, and Sleep Medicine at the University of California San Diego. He is Section Editor for UpToDate topics on pulmonary vascular disease.
Dr. George Mallory is Professor of Pediatrics at Baylor College of Medicine, and Section Editor for UpToDate topics on pediatric pulmonology.Segment on edoxaban versus low molecular weight heparin for venous thromboembolism in cancer patients (Dr. Jess Mandel):
- Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med 2018; 378:615.
Segment on tezacaftor-ivacaftor for cystic fibrosis (Dr. George Mallory):
- Taylor-Cousar JL, Munck A, McKone EF, et al. Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del. N Engl J Med 2017; 377:2013.
- Rowe SM, Daines C, Ringshausen FC, et al. Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis. N Engl J Med 2017; 377:2024.
Jess Mandel, MD Nothing to disclose
George Mallory, MD Nothing to disclose
Management of suicide risk in children and adolescents; Increasing prevalence of syphilis in the US
Date Released: Feb 7 2018
Today’s episode of UpToDate Talk features Dr. Gregory Simon discussing the management of suicide risk in children and adolescents, and Dr. Khalil Ghanem discussing the increasing prevalence of syphilis in the United States. The second segment begins at 18:10. Dr. Nancy Sokol hosts.
Dr. Gregory Simon is a psychiatrist and senior investigator at the Kaiser Permanente Washington Health Research Institute. He leads the Mental Health Research Network in the US and is an UpToDate author for topics on suicide.
Dr. Khalil Ghanem is Associate Professor of Medicine at the Johns Hopkins University School of Medicine and a specialist in infectious diseases. Dr. Ghanem is an UpToDate author on a number of topics on sexually transmitted infections.Segment on management of suicide risk in children and adolescents (Dr. Simon):
- Morgan C, Webb RT, Carr MJ, et al. Incidence, clinical management, and mortality risk following self-harm among children and adolescents: cohort study in primary care. BMJ 2017; 359:j4351.
Segment on increasing prevalence of syphilis in the US (Dr. Ghanem):
- United States Centers for Disease Control and Prevention. Sexually transmitted disease surveillance, 2016. https://www.cdc.gov/std/stats16/Syphilis.htm (Accessed on October 05, 2017).
Gregory Simon, MD, MPH Grant/Research/Clinical Trial Support: Novartis Pharmaceuticals [Depression in psoriasis].
Khalil Ghanem, MD, PhD Nothing to disclose
Frequency for dosing of oral iron; Risk of late recurrence after adjuvant endocrine therapy for breast cancer
Date Released: Jan 24 2018
In this episode of UpToDate Talk, Dr. Stanley Schrier joins us to discuss an article from Lancet Haematology on a new paradigm for the dosing of oral iron, and Dr. Dan Hayes discusses his meta-analysis from the New England Journal of Medicine on the risk of late recurrence after adjuvant endocrine therapy for breast cancer. Dr. Jennifer Tirnauer hosts. Figure on hepcidin in UpToDate (referenced in the segment on dosing for oral iron)
Dr. Stanley Schrier is Professor of Medicine at the Stanford University Medical Center, as well as an Editor-in-Chief, Section Editor, and Author in Hematology for UpToDate.
Dr. Dan Hayes is Professor of Medicine at the University of Michigan School of Medicine and a Section Editor and Author in Oncology for UpToDate.Segment on frequency for dosing of oral iron (Dr. Schrier):
- Stoffel NU, Cercamondi CI, Brittenham G, et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematol 2017; 4:e524.
Segment on risk of late recurrence after adjuvant endocrine therapy for breast cancer (Dr. Hayes):
- Pan H, Gray R, Braybrooke J, et al. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med 2017; 377:1836
Stanley L Schrier, MD Nothing to disclose
Daniel F Hayes, MD Grant/Research/Clinical Trial Support: Janssen R&D, LLC [Breast cancer (Abiraterone)]; Menarini Silicon Biosystems, LLC [Breast cancer (CellSearch)]; Puma Biotechnology [Breast cancer (Neratinib)]; Pfizer [Breast cancer (Palbociclib)]; AstraZeneca [Breast cancer (Circulating tumor cells)]; Eli Lilly and Company [Breast cancer]. Speaker's Bureau: Lilly Oncology (Breast cancer). Patent Holder: Immunicon Corporation [Inventor (05725638.0-1223-US2005008602)]; University of Michigan [Inventor (US 8,790,878 B2)]; University of Michigan [Inventor (US 8,951,484 B2)]. Equity Ownership/Stock Options: Oncimmune LLC [Stock]; Inbiomotion [Stock]. Other Financial Interest: Menarini Silicon Biosystems [Breast cancer (CellSearch)]; University of Michigan [Inventor (US 8,790,878 B2)].
Revised recommendations for endoscopy in dyspepsia; New hypertension criteria in ACC/AHA guidelines
Date Released: Jan 10 2018
This edition of UpToDate Talk features Dr. Nicholas Talley, who joins us to discuss the evaluation and management of dyspepsia in adults, and Dr. William White, who discusses the new ACC/AHA guidelines for the evaluation and management of high blood pressure in adults. Dr. April Eichler hosts.
Dr. Nicholas Talley is Professor of Medicine and Pro Vice-Chancellor of Global Research at the University of Newcastle in Australia. He is a Section Editor in Gastroenterology for UpToDate and is past president of the Australasian College of Physicians.
Dr. William White is Professor of Medicine and Chief of Hypertension and Clinical Pharmacology at the University of Connecticut School of Medicine. He is a Section Editor in Nephrology and Hypertension for UpToDate and is past president of the American Society of Hypertension.Segment on revised recommendations for endoscopy in dyspepsia (Dr. Nicholas Talley) :
- Moayyedi PM, Lacy BE, Andrews CN, et al. ACG and CAG Clinical Guideline: Management of Dyspepsia. Am J Gastroenterol 2017; 112:988.
Segment on new hypertension criteria in ACC/AHA guidelines (Dr. William White):
- Whelton PK, Carey RM, Aronow WS, et al. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2017.
Nicholas J. Talley, MD, PhDGrant/Research Support: Rome Foundation; Abbott Pharmaceuticals; Commonwealth Diagnostics Laboratories; Pfizer; Salix [Irritable bowel syndrome]; Prometheus Laboratories Inc [Irritable bowel syndrome (IBS Diagnostic)]; Janssen [Constipation]. Consultant/Advisory Boards: Adelphi Values [Functional dyspepsia (patient-reported outcome measures)]; (Budesonide)]; GI therapies [Chronic constipation (Rhythm IC)]; Sax Institute, Allergan PLC, Yuhan. Patent Holder: Biomarkers of irritable bowel syndrome [Irritable bowel syndrome]; Licensing Questionairre (Mayo); Nestec European Patents.
William B. White, MDGrant/Research/Clinical Trial Support: NIH [Vascular medicine]. Consultant/Advisory Boards: Data Safety Monitoring Boards: Teva [Multiple sclerosis (Laquinimod)]; Lundbeck [Hypotension (Droxidopa)]; Steering Committees: Takeda [Diabetes (Alogliptin)], Relypsa [Hyperkalemia (Patiromer)]; Cardiovascular End Point Committees: Takeda [Gout (Febuxostat)]; Forest [COPD (Roflumilast and Aclidinium)]; Roche [Anemia (Mircera)]; AstraZeneca [COPD].